S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,272.57 (-0.02%)
DOW   33,544.99 (-0.22%)
QQQ   354.00 (-0.06%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
LON:IMM

ImmuPharma (IMM) Share Forecast, Price & News

GBX 1.82
-0.08 (-4.31%)
(As of 04:25 PM ET)
Compare
Today's Range
1.73
1.92
50-Day Range
1.81
2.59
52-Week Range
1.36
4.10
Volume
626,082 shs
Average Volume
1.41 million shs
Market Capitalization
£7.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMM stock logo

About ImmuPharma (LON:IMM) Stock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

IMM Price History

IMM Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
ImmuPharma shares jump 6.5% after FDA update
ImmuPharama eyes clinical trial progress
ImmuPharma eyes clinical trial progress
ImmuPharma "looking forward" to upcoming FDA meetings
ImmuPharma partner gets FDA meeting date
ImmuPharma rises 4% after it reveals headway with lead asset
See More Headlines
Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Company Calendar

Last Earnings
9/30/2020
Today
9/27/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
£-2,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£94,819.00
Cash Flow
GBX 0.09 per share

Miscellaneous

Free Float
N/A
Market Cap
£7.58 million
Optionable
Not Optionable
Beta
1.39
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy Paul McCarthy XIV (Age 66)
    FCCA, M.B.A., MBA, Chairman & CEO
    Comp: $106.5k
  • Dr. Timothy Gary Franklin M.B.A.
    Ph.D., COO & Director
  • Ms. Lisa Baderoon
    Head of Investor Relations & Non Exec. Director
  • Dr. Jean-Marie Geiger PharmD
    MD, Head of Clinical Devel.
  • Dr. Laura Mauran-Ambrosino
    Chief Scientific Officer of ImmuPharma Biotech
  • Ms. Lara E. Sucheston-Campbell
    Head of Clinical & Medical Affairs
  • Dr. Sébastien R. Goudreau Ph.D.
    CEO of ImmuPharma Biotec & Director













IMM Stock - Frequently Asked Questions

How have IMM shares performed in 2023?

ImmuPharma's stock was trading at GBX 1.84 at the start of the year. Since then, IMM stock has decreased by 1.0% and is now trading at GBX 1.82.
View the best growth stocks for 2023 here
.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) released its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 1.82.

How much money does ImmuPharma make?

ImmuPharma (LON:IMM) has a market capitalization of £7.58 million and generates £94,819.00 in revenue each year. The company earns £-2,990,000.00 in net income (profit) each year or GBX (0.01) on an earnings per share basis.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The official website for the company is www.immupharma.org. The company can be reached via phone at +44-20-71524080.

This page (LON:IMM) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -